G0544
GR 103691
≥98% (HPLC), solid
别名:
4′-Acetyl-N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-[1,1′-biphenyl]-4-carboxamide
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C30H35N3O3
化学文摘社编号:
分子量:
485.62
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
solid
color
white
solubility
DMSO: soluble >5 mg/mL at 60 °C
originator
GlaxoSmithKline
storage temp.
2-8°C
SMILES string
COc1ccccc1N2CCN(CCCCNC(=O)c3ccc(cc3)-c4ccc(cc4)C(C)=O)CC2
InChI
1S/C30H35N3O3/c1-23(34)24-9-11-25(12-10-24)26-13-15-27(16-14-26)30(35)31-17-5-6-18-32-19-21-33(22-20-32)28-7-3-4-8-29(28)36-2/h3-4,7-16H,5-6,17-22H2,1-2H3,(H,31,35)
InChI key
JARNORYOPMINDY-UHFFFAOYSA-N
Gene Information
rat ... Htr1a(24473)
Application
GR 103691 has been used as a D3 receptor antagonist to test its:
- inducing effect on prepulse inhibition (PPI)
- suppressive effect of motor behavior in rats
- inhibitory effect on chemotaxis in newly excysted juvenile C. sinensis (CsNEJs)
Biochem/physiol Actions
D3 dopamine receptor antagonist.
GR 103691 increases the monosynaptic “stretch” reflex (MSR) amplitude in mice by its potent D3 receptor antagonist functionality. It inhibits the PD 128,907 mediated γ-aminobutyric acid (GABA) release.
Features and Benefits
This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)